• Cardiff Oncology sued Nerviano Medical Sciences on May 19, 2026, seeking to block termination of a 2017 onvansertib license agreement.
• The complaint seeks an injunction to keep the agreement in force, a declaratory judgment of no breach, and additional relief.
• Nerviano notified the company on May 27, 2026 that it was terminating the agreement under Section 11.3.
• Nerviano alleges a breach tied to inventorship disputes on two U.S. patents, citing failure to add Barbara Valsasina as a joint inventor.
• Nerviano also alleges insufficient commercially reasonable efforts to develop onvansertib and secure regulatory approvals; Cardiff disputes the termination as ineffective.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-248711), on May 29, 2026, and is solely responsible for the information contained therein.